# Enveda Biosciences raises USD 311 million in Series E financing

On 2026-09-24, according to Xiniu Data, Enveda Biosciences completed Series E financing, raising USD 311 million. Investors were lead investor Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed and others. The company is a developer of AI natural product drugs.



Canonical: https://uniquebase.ai/news/f138535b-b046-46b6-b65d-9519a7ba8390
Stable identifier: f138535b-b046-46b6-b65d-9519a7ba8390
Snapshot captured: 2026-10-15T14:23:27.067Z
English updated: 2026-10-15T21:56:38.837Z

## Connected profiles

- [Alderline Group](/institutions/alderline-group)
- [Baillie Gifford](/institutions/baillie-gifford)
- [Catalio Capital Management](/institutions/catalio-capital-management)
- [Digitalis Ventures](/institutions/digitalis-ventures)
- [Dimension](/institutions/dimension)
- [Durable Capital Partners](/institutions/durable-capital-partners)
- [Enveda](/companies/enveda)
- [FPV Ventures](/institutions/fpv-ventures)
- [ICONIQ Growth](/institutions/iconiq-growth)
- [Kinnevik](/institutions/kinnevik)
- [Lifeforce Capital](/institutions/lifeforce-capital)
- [Lightspeed Venture Partners](/institutions/lightspeed-venture-partners)
- [Lux Capital](/institutions/lux-capital)
- [Premji Invest](/institutions/premji-invest)
- [Surveyor Capital](/institutions/surveyor-capital)
- [T.Rowe Price investment Management](/institutions/t-rowe-price-investment-management)
- [True Ventures](/institutions/true-ventures)

## Sources

- No source links are available for this profile.